| ABSTRACT Objective:To systematically evaluate the clinical efficacy and safety of Shenqi Fuzheng injection in treatment of cerebral infarction. Methods:Randomized controlled trials (RCTs) regarding Shenqi Fuzheng injection in the treatment of cerebral infarction in CNKI, VIP, Wanfang Database, PubMed, Cochrane Library, Embase by September 2016. Quality of included RCTs was evaluated by The Cochrane Risk of Bias Assessment Tool, and then the required information was extracted and Meta analyzed by RevMan 5.3 software. Results:A total of 7 RCTs with 535 participants were included. In the Meta analysis, Shenqi Fuzheng injection could achieve a better effect than the group without Shenqi Fuzheng injection in respect of total effective rate (RR=1.31, 95%CI: 1.19 1.43, P<0.000 01). In addition, it could decrease the index of fibrinogen (MD=-1.36, 95%CI: -1.47 -1.25,P<0.000 01), the plasma viscosity (MD=-0.31, 95%CI: -0.54 -0.07, P=0.01), and achieve a better effect in the degree of neurological impairment. Conclusion: Shenqi Fuzheng injection is more effective in improving the total effective rate, the hemorrheological indexes and the neurologic impairment. However, the evidence of Shenqi Fuzheng injection for treating cerebral infarction requires large scale and double blind RCTs to substantiate these findings. |
